Page 30 - Cancer Update Spring 2019 Vol. 8 Issue 1

28
August 2018 to January 2019
RECENT PUBLICATIONS
FROM BAYLOR CHARLES A. SAMMONS CANCER CENTER
Aguilar KM, Winfree KB, Muehlenbein CE, Zhu YE, Wilson T, Wetmore S, Nadler ES. Treatment Patterns by EGFR Mutation Status in Non-Small Cell Lung Cancer Patients in the USA: A Retrospective Database Analysis. Adv Ther. 2018 Nov;35(11):1905-1919.
Bresalier RS, Souza RF. A Goblet (Cell) Half Full: What Do We Really Know About Barrett’s Esophagus-A Tribute to Emmet Keeffe. Dig Dis Sci. 2018 Aug;63(8):1985-1987.
Conrad C, Fleshman JW Jr. Minimally Invasive Oncologic Surgery, Part I. Surg Oncol Clin N Am. 2019 Jan;28(1):xv-xvii.
Elwir S, Anugwom C, Connor EK, Giama NH, Ndzengue A, Menk J, Mohamed EA, Roberts LR, Hassan M. Barriers in Hepatitis C Treatment in Somali Patients in the Direct Acting Antiviral Therapy Era. J Natl Med Assoc. 2018 Dec;110(6):556-559.
Ettl J, Quek RGW, Lee KH, Rugo HS, Hurvitz S, Gonçalves A, Fehrenbacher L, Yerushalmi R, Mina LA, Martin M, Roché H, Im YH, Markova D, Bhattacharyya H, Hannah AL, Eiermann W, Blum JL, Litton JK. Quality of life with talazoparib versus physician’s choice of chemotherapy in patients with advanced breast cancer and germline BRCA1/2 mutation: patient-reported outcomes from the EMBRACA phase III trial. Ann Oncol. 2018 Sep 1;29(9):1939-1947.
Eustace AJ, Conlon NT, McDermott MSJ, Browne BC, O’Leary P, Holmes FA, Espina V, Liotta LA, O’Shaughnessy J, Gallagher C, O’Driscoll L, Rani S, Madden SF, O’Brien NA, Ginther C, Slamon D, Walsh N, Gallagher WM, Zagozdzon R, Watson WR, O’Donovan N, Crown J.
Development of acquired resistance to lapatinib may sensitise HER2-positive breast cancer cells to apoptosis induction by obatoclax and TRAIL. BMC Cancer. 2018 Oct 11;18(1):965.
Fathi AT, Erba HP, Lancet JE, Stein EM, Ravandi F, Faderl S, Walter RB, Advani AS, DeAngelo DJ, Kovacsovics TJ, Jillella A, Bixby D, Levy MY, O’Meara MM, Ho PA, Voellinger J, Stein AS. A phase 1 trial of vadastuximab talirine combined with hypomethylating agents in patients with CD33 positive AML. Blood. Sep 13;132(11):1125-1133.
Fleshman J, Branda ME, Sargent DJ, Boller AM, George VV, Abbas MA, Peters WR Jr, Maun DC, Chang GJ, Herline A, Fichera A, Mutch MG, Wexner SD, Whiteford MH, Marks J, Birnbaum E, Margolin DA, Larson DW, Marcello PW, Posner MC, Read TE, Monson JRT, Wren SM, Pisters PWT, Nelson H. Disease- free Survival and Local Recurrence for Laparoscopic Resection Compared With Open Resection of Stage II to III Rectal Cancer: Follow-up Results of the ACOSOG Z6051 Randomized Controlled Trial. Ann Surg. 2018 Aug 3. doi: 10.1097/SLA.0000000000003002. [Epub ahead of print]
Garces S, Khoury JD, Kanagal- Shamanna R, Salem A, Wang SA, Ok CY, Hu S, Patel KP, Routbort MJ, Luthra R, Tang G, Schlette EJ, Bueso- Ramos CE, Medeiros LJ, Loghavi S. Chronic lymphocytic leukemia with proliferation centers in bone marrow is associated with younger age at initial presentation, complex karyotype and TP53 disruption. Hum Pathol. 2018 Dec;82:215-231.
8 / Innovative Immuno-Oncology Clinical 13 / A Multidisciplinary Approach 23 / Neuroendocrine Cancer in the Skin: A Publication for Baylor Scott & White Health’s Oncology Program Trial Using Natural Killer Cells to Neuroendocrine Cancer Merkel Cell Carcinoma